South Africa is rolling out lenacapavir, a twice-yearly injectable drug for HIV prevention that the president calls a turning ...
The Lenacapavir injections were compared to the current standard of HIV prevention—a pill called Truvada or Descovy taken ...
Beyond local manufacturing plans, government is also working with international partners to accelerate access to lower-cost ...
Gilead’s lenacapavir has been on the market since 2022, when it was approved in the U.S. as Sunlenca for twice-yearly ...
South Africa launches lenacapavir, a twice-yearly injectable HIV prevention drug proven highly effective, aiming to curb new infections amid access and rollout challenges ...
The Gauteng Health Department has begun a phased rollout of Lenacapavir, a twice-yearly HIV prevention injection now ...
Phase 3 ISLEND-1 and ISLEND-2 trials met primary endpoints at week 48, showing a novel, once-weekly oral single-tablet regimen is noninferior to daily B/F/TAF or standard ART.
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
South Africa ushers in a new era in its HIV prevention response today, officially launching the game-changing Lenacapavir ...
The medication, which is administered twice a year, is intended to help HIV-negative people who are at a high risk of ...
A new twice-yearly HIV prevention injection could transform South Africa's fight against the epidemic — but U.S. aid cuts and ...
Africanews on MSN
Ramaphosa hails Lenacapavir roll out as turning point in HIV fight
South African President, Cyril Ramaphosa holds a box of Lenacapavir during the official launch of the drug's rollout ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results